Serious ophthalmic pathology compromising vision in HCV/HIV co-infected patients treated with peginterferon alpha-2b and ribavirin

AIDS

Volumn 18, Issue 13, 2004, Pages 1805-1809

  Farel, Claire ^a   Suzman, Daniel L ^a   McLaughlin, Mary ^a   Campbell, Colleen ^a   Koratich, Chad ^a   Masur, Henry ^b   Metcalf, Julia A ^a   Robinson, Michael R ^c   Polis, Michael A ^a   Kottilil, Shyam ^a,d  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c NATIONAL EYE INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Color vision; HCV HIV co infection; Hepatitis c; HIV; Ophthalmology; Pegylated interferon; Ribavirin

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; ARTICLE; CATARACT; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL TRIAL; COLOR VISION; COLOR VISION DEFECT; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG WITHDRAWAL; EYE DISEASE; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; OPEN STUDY; OPHTHALMOSCOPY; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROSPECTIVE STUDY; T LYMPHOCYTE; VISUAL ACUITY; VISUAL FIELD;

ADULT; CATARACT; COLOR VISION DEFECTS; EYE DISEASES; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; INTERFERON ALFA-2B; MIDDLE AGED; PROSPECTIVE STUDIES; RIBAVIRIN; VISION DISORDERS;

EID: 4444248245     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200409030-00009     Document Type: Article

References (10)

1. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347:975-982.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358:958-965.
3. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-1058.
4. Gonzalez SA, Talal AH. Hepatitis C virus in human immunodeficiency virus-infected individuals: an emerging comorbidity with significant implications. Semin Liver Dis 2003; 23:149-166.
5. Jain K, Lam WC, Waheeb S, Thai Q, Heathcote J. Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol 2001; 85:1171-1173.
6. Schulman JA, Liang C, Kooragayala LM, King J. Posterior segment complications in patients with hepatitis C treated with interferon and ribavirin. Ophthalmology 2003; 110:437-442.
7. Manesis EK, Moschos M, Brouzas D, Kotsiras J, Petrou C, Theodosiadis G, et al. Neurovisual impairment: a frequent complication of alpha-interferon treatment in chronic viral hepatitis. Hepatology 1998; 27:1421-1427.
8. Barron GJ, Tepper L, Iovine G. Ocular toxicity from ethambutol. Am J Ophthalmol 1974; 77:256-260.
9. Sugano S, Suzuki T, Watanabe M, Ohe K, Ishii K, Okajima T. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C. Am J Gastroenterol 1998; 93:2441-2444.
10. Perez-Olmeda M, Nunez M, Romero M, Morales D, Romero M, Ochoa A, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003; 17:1023-1028.